The DOI matches its Crossref record.
Cytochrome P450 Gene Polymorphism and Cancer
Abstract
Human cytochrome P450 (CYP) enzymes play a key role in the metabolism of drugs and environmental chemicals. Several CYP enzymes metabolically activate procarcinogens to genotoxic intermediates. Phenotyping analyses revealed an association between CYP enzyme activity and the risk to develop several forms of cancer. Research carried out in the last decade demonstrated that several CYP enzymes are polymorphic due to single nucleotide polymorphisms, gene duplications and deletions. As genotyping procedures became available for most human CYP, an impressive number of association studies on CYP polymorphisms and cancer risk were conducted. Here we review the findings obtained in these studies regarding CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP8A1 and CYP21 gene polymorphisms. Consistent evidences for association between CYP polymorphisms and lung, head and neck, and liver cancer were reported. Controversial findings suggest that colorectal and prostate cancers may be associated to CYP polymorphisms, whereas no evidences for a relevant association with breast or bladder cancers were reported. We summarize the available information related to the association of CYP polymorphisms with leukaemia, lymphomas and diverse types of cancer that were investigated only for some CYP genes, including brain, esophagus, stomach, pancreas, pituitary, cervical epithelium, melanoma, ovarian, kidney, anal and vulvar cancers. This review discusses on causes of heterogeneity in the proposed associations, controversial findings on cancer risk, and identifies topics that require further investigation. In addition, some recommendations on study design, in order to obtain more conclusive findings in further studies, are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“, 2006), and several forms of cancer (Agundez, 2004; Rodriguez-Antona et al., 2010).”
BackgroundMartignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Nebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Oxidative Stress and Oxidative Damage in Carcinogenesis
Klaunig, J. E., Kamendulis, L. M., & Hocevar, B. A. (2010) · Toxicologic Pathology · doi:10.1177/0192623309356453 · Cited by 957
Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 575
(EFSA), E. F. S. A. (2008) · EFSA Journal · doi:10.2903/j.efsa.2008.724 · Cited by 568
Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611692200 · Cited by 478
Biological activity of piceatannol: Leaving the shadow of resveratrol
Piotrowska, H., Kucinska, M., & Murias, M. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.11.001 · Cited by 476
Oxidative stress and oxidative damage in chemical carcinogenesis
Klaunig, J. E., Wang, Z., Pu, X., & Zhou, S. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.11.028 · Cited by 470
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Chromosomal aberrations and SCEs as biomarkers of cancer risk
Norppa, H., Bonassi, S., Hansteen, I.-L., Hagmar, L., Strömberg, U., Rössner, P., Boffetta, P., Lindholm, C., Gundy, S., Lazutka, J., et al. (2006) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2006.05.030 · Cited by 293
Metadata
- Authors
- Agundez, J.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-06-01
- Volume
- 5
- Issue
- 3
- Pages
- 211-224
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2071936413
- Cited by
- 292
- References
- 0
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.